TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26718605
Drug: Oral delafloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral delafloxacin (450 mg)
Study: 15960642
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% 0.75 ml.kg(‐1)
Study: 15960642
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% 0.75 ml.kg(‐1) plus clonidine 1 microg.kg(‐1)
Study: 15960642
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% 0.75 ml.kg(‐1) plus ketamine 0.5 mg.kg(‐1)
Study: 10348223
Drug: Malarone (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Malarone (250 mg of atovaquone/100 mg of proguanil hydrochloride per tablet)
Study: 7491835
Drug: Transdermal 17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17 beta‐estradiol matrix patch (0.05 mg/day)
Study: 9573748
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogens (0.625 mg/day)
Study: 7491835
Drug: Transdermal 17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17 beta‐estradiol matrix patch
Study: 9467549
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogens
Study: 161858
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive containing 0.05 mg of ethinylestradiol and 0.100 mg or 0.125 mg of a new progestogen (17 alpha‐ethinyl‐18‐methylene‐4‐estren‐17 beta‐ol)
Study: 31172416
Drug: pegylated-interferon (peg-IFN)
Normalized name: Pegylated interferon alpha-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pegylated-interferon (peg-IFN) consolidation treatment for 48 weeks
Study: 31172416
Drug: nucleos(t)ide analogue
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: nucleos(t)ide analogue (NA) consolidation treatment for 48 weeks
Study: 29962050
Drug: Evolocumab 420
Normalized name: evolocumab 420 in 3.5 ML Cartridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab 420 mg every month (QM)
Study: 26862823
Drug: Psychoeducational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychoeducational intervention (8 weekly sessions)
Study: 16403233
Drug: Intravenous cimetidine
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cimetidine 800 mg per day
Study: 16403233
Drug: Oral omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral omeprazole 40 mg per day
Study: 8499355
Drug: Both twins
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both twins on identical tapering regimen of corticosteroids over 3 months
Study: 3318799
Drug: Scopolamine 0.6
Normalized name: scopolamine 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine 0.6 mg with d-amphetamine 5 mg
Study: 3318799
Drug: Scopolamine 0.6
Normalized name: scopolamine 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine 0.6 mg with d-amphetamine 5 mg and neostigmine 15 mg
Study: 3318799
Drug: Neostigmine 15
Normalized name: neostigmine 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 15 mg
Study: 31617447
Drug: Mastery Learning
Normalized name: Noxzema Clean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mastery Learning (ML)
Study: 15963119
Drug: LHRH agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRH agonist treatment for 3-5 months before radical radiotherapy
Study: 11393207
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate cream (Temovate®) applied twice daily for 3 or 4 weeks
Study: 9278462
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (tinzaparin)
Study: 3501728
Drug: Ro 15-8081
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 15-8081 (10 mg)
Study: 3501728
Drug: Ro 15-8081
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 15-8081 (25 mg)
Study: 3501728
Drug: Ro 15-8081
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 15-8081 (50 mg)
Study: 10896014
Drug: Codeine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine (60 mg)
Study: 29753374
Drug: Pentoxifylline 400mg
Normalized name: PENTOXIFYLLINE 400MG TAB,SA
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline 400mg b.i.d. plus losartan 50mg daily
Study: 27124177
Drug: Guided neoadjuvant
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided neoadjuvant chemotherapy (guided‐NACT)
Study: 27124177
Drug: Conventional neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional neoadjuvant chemotherapy (conventional‐NACT)
Study: 26404395
Drug: Levosulpiride 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosulpiride 50 mg tablets, 3 times daily
Study: 26404395
Drug: Levosulpiride 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosulpiride 50 mg injection (IM), twice daily
Study: 21360537
Drug: Subareolar injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subareolar injection of methylene blue (MB)
Study: 21360537
Drug: Peritumoral injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritumoral injection of methylene blue (MB)
Study: 27737664
Drug: etoricoxib 60
Normalized name: etoricoxib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: etoricoxib 60 mg
Study: 27737664
Drug: etoricoxib 90
Normalized name: etoricoxib 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: etoricoxib 90 mg
Study: 17184507
Drug: [(13)C]‐acetate breath
Approvals — FDA: no, EMA: no, PMDA: no
Description: [(13)C]‐acetate breath test (ABT) with 100 mg [(13)C]‐acetate and 200 kcal liquid meal
Study: 17184507
Drug: High viscosity
Normalized name: Mineral Oil, High Viscosity
DrugBank: Light mineral oil (DB11579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High viscosity meal (gel-forming agent added)
Study: 1484192
Drug: Controlled-release morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release morphine (CRM) suspension (SAR 213)
Study: 1484192
Drug: Controlled-release morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release morphine (CRM) tablets (Moscontin)
Study: 24947950
Drug: No prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prophylactic antibiotics
Study: 27885425
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (ITM) - single injection 4 µg/kg before skin incision (n = 23)
Study: 27885425
Drug: Intravenous opioids
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous opioids (IVO) - iv remifentanil infusion during surgery followed by i.v. bolus of morphine, 0.15 mg/kg before the end of surgery (n = 26)
Study: 21299684
Drug: Caudal block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal block with 0.7 ml·kg(‐1) of 1.0% lidocaine containing epinephrine at 5 μg·ml(‐1)
Study: 11758229
Drug: M group
Normalized name: malarial plasmodium group immunoserum rabbit
Approvals — FDA: no, EMA: no, PMDA: no
Description: M group and L group (moderate and major renal dysfunction)
Study: 9218948
Drug: Erythromycin 500
Normalized name: erythromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 500 mg orally every 8 h for 10 days
Study: 3307487
Drug: 0.7 ml
Normalized name: ethanol 0.7 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7 ml of Alcohol per kg body weight
Study: 3307487
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml of Alcohol per kg body weight
Study: 23150720
Drug: Triple-drug chemolipiodolization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-drug chemolipiodolization with sponge embolization (Arm 1)
Study: 23150720
Drug: Triple-drug chemolipiodolization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-drug chemolipiodolization without embolization (Arm 2)
Study: 23150720
Drug: Single-drug chemolipiodolization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-drug chemolipiodolization with sponge embolization (Arm 3)
Study: 2507875
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (n = 6) - saline injections
Study: 16806
Drug: Liquid Maalox,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid Maalox, 30 ml, 1 and 3 hr after a meal
Study: 31616932
Drug: Avocado diet
Normalized name: Avocado
DrugBank: Avocado (DB10504)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avocado diet (1 Hass avocado, ∼136 g per day)
Study: 24488582
Drug: lynestrenol (LYN)
Normalized name: lynestrenol
DrugBank: Lynestrenol (DB12474)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lynestrenol (LYN) 15 mg/d
Study: 24488582
Drug: micronized progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: micronized progesterone (MP) 200 mg/d
Study: 20804358
Drug: Therapy tapering
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy tapering (occlusion reduced from full-time to 50% of waking hours, then to 25%, and discontinued at week 8)
Study: 20804358
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (abrupt cessation and therapy tapering)
Study: 29532635
Drug: Broccoli sprouts
Normalized name: broccoli sprout extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broccoli sprouts incorporated in gels (protein, fiber, lipid)
Study: 29532635
Drug: Gels rich
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gels rich in precursors (glucoraphanin and glucoiberin)
Study: 21940695
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injections to parotid and submandibular glands (5 individuals)
Study: 21940695
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injections to submandibular glands only (1 individual)
Study: 20227758
Drug: Mipomersen 200
Normalized name: mipomersen 200 mg/mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mipomersen 200 mg subcutaneously every week for 26 weeks
Study: 14523294
Drug: 1-week-on, 1-week-off
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-week-on, 1-week-off therapy
Study: 14523294
Drug: Triple nucleotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple nucleotide therapy
Study: 1458665
Drug: 5% amorolfine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% amorolfine nail lacquer, once-weekly
Study: 1458665
Drug: 5% amorolfine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% amorolfine nail lacquer, twice-weekly
Study: 25527663
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (OCs)
Study: 10230741
Drug: Fluid extract
Normalized name: FLUID EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid extract of Echinacea purpurea (4 mL twice a day)
Study: 10230741
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 mL juice twice a day)
Study: 1867225
Drug: Oral sustained-release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sustained-release verapamil (verapamil-SR)
Study: 6344906
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment combined with compression bandages
Study: 27223668
Drug: Levosulpiride (25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosulpiride (25-50 mg/d)
Study: 27223668
Drug: Haloperidol (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (10-20 mg/d)
Study: 14764127
Drug: Solifenacin 5
Normalized name: solifenacin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin 5 mg once daily
Study: 18054420
Drug: silymarin (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: silymarin (0.8 g/day)
Study: 18054420
Drug: silymarin+yacon (0.8+2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: silymarin+yacon (0.8+2.4 g/day)
Study: 18054420
Drug: silymarin+maca (0.6+0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: silymarin+maca (0.6+0.2 g/day)
Study: 18054420
Drug: maca (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: maca (0.6 g/day)
Study: 18054420
Drug: maca (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: maca (high doses)
Study: 12755242
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg prostaglandin E2 vaginal tablets
Study: 10996361
Drug: Correlation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation of CD105 with active TGFbeta1 and (a+l)TGFbeta1
Study: 9229826
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate aerosol treatment
Study: 23122405
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg of PPTA
Study: 23122405
Drug: 0.4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/kg of PPTA
Study: 23122405
Drug: 0.6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/kg of PPTA
Study: 20187249
Drug: Gene therapy
Normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene therapy approaches to increase levels of endogenous dopamine or enhance the function of levodopa
Study: 20187249
Drug: Gene therapy
Normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene therapy approaches to normalize basal ganglia circuitry by reducing PD-related overactivity of specific brain structures
Study: 19667500
Drug: Venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine XR (37.5 to 225 mg once daily)
Study: 26881208
Drug: Daily intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily intranasal deslorelin (GnRHa) with concurrent administration of low-dose estradiol (E2) ± testosterone (T) for 6 months
Study: 26881208
Drug: Daily intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily intranasal deslorelin (GnRHa) with concurrent administration of low-dose estradiol (E2) ± testosterone (T)
Study: 23595613
Drug: Rebamipide 100
Normalized name: Rebamipide 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rebamipide 100 mg three times daily for 4 weeks
Study: 15367828
Drug: Valsartan (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (80 mg/day)
Study: 18047925
Drug: Spironolactone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (25 mg/day) for 3 months
Study: 15650042
Drug: Psychosocial counselling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial counselling intervention (three sessions with a social worker trained in Experiential Psychosocial Therapy: one before, one during, and one after the first IVF cycle)
Study: 12395333
Drug: Tamoxifen 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 120 mg/d (TMX120)
Study: 12395333
Drug: Tamoxifen 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 60 mg/d (TMX60)
Study: 10092165
Drug: Muscle relaxation
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muscle relaxation training (30 minutes, twice a week for 10 weeks)
Study: 7594701
Drug: cp-45 vaccine
Normalized name: L1 protein, human papillomavirus type 45 vaccine
DrugBank: Human papillomavirus type 45 L1 capsid protein antigen (DB10312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cp-45 vaccine (10^4 or 10^5 TCID50)
Study: 7594701
Drug: cp-45 vaccine
Normalized name: L1 protein, human papillomavirus type 45 vaccine
DrugBank: Human papillomavirus type 45 L1 capsid protein antigen (DB10312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cp-45 vaccine (10^5 TCID50)
Study: 6576204
Drug: Radiation doses
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation doses of less than or equal to 18 Gy
Study: 6576204
Drug: Radiation doses
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation doses of 24 Gy
Study: 6576204
Drug: Intensive systemic
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive systemic reinduction therapy
Study: 30859618
Drug: Monovalent PHF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent PHF vaccine administered at separate sites
Study: 30859618
Drug: Multivalent PHF/Rabies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivalent PHF/Rabies vaccine administered at a single site
Study: 28406122
Drug: Mechanical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical treatment (Group M)
Study: 28406122
Drug: Diode laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diode laser disinfection (Group L)
Study: 28406122
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of mechanical treatment and diode laser (Group M + L)
Study: 25641925
Drug: Weight loss
Normalized name: HERBAL WEIGHT LOSS AID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight loss during neoadjuvant chemotherapy (NCT)
Study: 25641925
Drug: Weight gain
Normalized name: Nutritional Supplement Oral Powder for Suspension [MUSCLE & WEIGHT GAINER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight gain during neoadjuvant chemotherapy (NCT)
Study: 24835038
Drug: Enhanced depression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced depression treatment for 6 months
Study: 19075991
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of cereal allergens
Study: 12918893
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of docetaxel (Taxotere) and capecitabine (Xeloda)
Study: 8732122
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release tablets of Tripterygium wilfordii (TW‐SR), 2 tablets, twice a day for 4 weeks
Study: 8732122
Drug: Tablets of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets of Tripterygium wilfordii (TW), 2 tablets, 3 times per day for 4 weeks
Study: 1831755
Drug: 2.4 g
Normalized name: ZINC OXIDE 12.4 g in 100 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 g eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids
Study: 1831755
Drug: 3.6 g
Normalized name: ALCOHOL 3.6 g EXTRACORPOREAL CLOTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 g eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids
Study: 30311987
Drug: Oral oncolytic
Normalized name: Telomerase Specific Replication-competent Oncolytic Adenovirus
DrugBank: Suratadenoturev (DB18672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oncolytic treatment
Study: 30517572
Drug: Topical formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical formulation containing chamomile microparticles coated with chitosan
Study: 30517572
Drug: Base formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Base formulation
Study: 30517572
Drug: Formulation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation with microparticles
Study: 26403703
Drug: Maternal breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal breast milk supplementation with 2g of a multinutrient supplement (Pré-Nan(®), Nestlé) added to expressed breast milk twice a day until a corrected age of 4-6 months.
Study: 24231400
Drug: Lee Silverman
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lee Silverman Voice Treatment-BIG (BIG; 16 hours over 4 weeks)
Study: 17333159
Drug: Gemfibrozil 600
Normalized name: gemfibrozil 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil 600 mg orally twice daily for 3 days
Study: 16279906
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron sucrose (7 mg iron/kg body weight, followed by five 200 mg infusions over 5 weeks)
Study: 16279906
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron sulfate (100-200 mg per day for 6 weeks)
Study: 9834991
Drug: Chest irradiation
Normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chest irradiation combined with chemotherapy
Study: 4776883
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (2,000 international units daily for three months)
Study: 4776883
Drug: Anticonvulsant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticonvulsant treatment
Study: 26206641
Drug: Mupirocin ointment
Normalized name: Mupirocin Ointment
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mupirocin ointment application (MOA)
Study: 23328389
Drug: Treprostinil diolamine
Normalized name: treprostinil diolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treprostinil diolamine (oral sustained release tablets), chronic dosing (twice-daily)
Study: 20977377
Drug: Monochromatic near-infrared
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monochromatic near-infrared light treatment (12 sessions of 30 minutes each over 4 weeks)
Study: 20977377
Drug: Monochromatic near-infrared
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monochromatic near-infrared light treatment
Study: 9371358
Drug: 3.375 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.375 g piperacillin-tazobactam every 6 hours
Study: 9371358
Drug: 4.5 g
Normalized name: Zosyn 4.5 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 g piperacillin-tazobactam every 8 hours
Study: 3914805
Drug: CSII (Continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSII (Continuous Subcutaneous Insulin Infusion)
Study: 3914805
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily mixed rapid and long acting insulin